So that platform continues to do very well. Our coronary business did excellent. We’re seeing nice results of agents in the U.S. We’ll be launching that in 2024, which really reverses any declining trend in drug-eluting stents, and that complex coronary business continues to do well. We saw a great strong growth in PI and endo, euro. We had some softness in our Neuromod business. We anticipate that to get better in the second half. So really, it’s a continued momentum. And what we’ll highlight at Investor Day is some of the questions we received today. We have some potential very big growth drivers with ongoing WATCHMAN momentum in our entire EP business with the launch of Cryo, which we anticipate in the third quarter this year, and FARAPULSE, which has been discussed at great length.
So just good momentum and extremely exciting launches coming that we’ll detail out at Investor Day.
Samantha Kurtz: Thanks so much.
Operator: Our next question comes from Matt Miksic with Barclays. Please go ahead.
Matthew Miksic: Hey. Thanks so much for taking the question and congrats on a super strong quarter. So really impressive breaking into double-digits. You are welcome. So Dan, I want to just follow up on cash flows and cash flow conversion and sort of what the puts and takes there have been in the first half? What your expectations are in the back half, and your intermediate long-term goals there? I’m sure you more about at the Analyst Meeting, but anything you can share now? And then also just on cash, if I could. You have so many things going on in that portfolio and in your our clinical programs, but I’d love to get your sort of posture on the business development front and your efforts to find and invest in additional technology and assets? Thanks.
Dan Brennan: Sure. So on free cash flow, I’m really happy with Q2. Strong free cash flow quarter, both sequentially and year-over-year. To your point, conversion, it’s an area of focus for us, an area of opportunity that has our attention, and one we’re looking to improve on as we go forward here. As I’ve said in the past, there’s a couple of kind of key reasons, one of which is our GAAP operating income is lower than some of our peers. We’re doing a pretty good job of closing that gap over time, and that will be a key contributor. And then the acquisitive nature of what we do is — can be a bit of a hamstring there, but I would look for — as you said, at Investor Day, I’d look for us to give some pretty concrete goals relative to what we think we can do over that LRP period in the next three years to improve the conversion ratio that we have.
And again, it’s a focus area for us and something that we will look to improve on going forward. And I think your second question was on cash and M&A, is that fair?
Matthew Miksic: Yeah, exactly. Yeah.
Dan Brennan: Yes. So I mean our capital allocation strategy has been remarkably consistent, right? It’s all about the number one priority being high-quality tuck-in M&A. It’s still our number one priority. We continue to look at opportunities in conjunction with our financial goals. We have closed two deals this year. The acquisition of Apollo closed in April, and then our acquisition of a stake in Acotec, the Chinese company, closed in February. So we’ve closed a couple this year. We continue to look to be active in the M&A space, and that remains our number one capital allocation priority.
Matthew Miksic: Thanks and congrats.
Dan Brennan: Thanks, Matt.
Operator: Our next question comes from Marie Thibault with BTIG. Please go ahead.
